Simplify Logo

Internship

Spring 2025 Co-op: Cell & Molecular Biology

Confirmed live in the last 24 hours

Prime Medicine

Prime Medicine

201-500 employees

Gene editing technology for genetic diseases

Biotechnology
Healthcare

Cambridge, MA, USA

Candidates must be local to the Boston/Cambridge area.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • B.S/M.S. candidate in Cell & Molecular Biology or related major
  • Basic knowledge of molecular biology, cell biology and biochemistry.
  • Excellent troubleshooting and communication skills
  • Ability to work independently and within a team
Responsibilities
  • Aseptic mammalian cell culture, including passaging and performing transfections to evaluate Prime Editor activity.
  • Cloning of Prime editor components into suitable expression vectors
  • DNA, RNA, and protein extraction from in vitro and in vivo samples
  • Sample preparation to confirm Prime Editing using various techniques including NGS, ddPCR, qPCR, and ELISAs
  • Data analysis, interpretation, and team presentation
  • Electronic lab notebook documentation

Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, Prime Medicine collaborates with research institutions and pharmaceutical companies to advance its technology and generate revenue through licensing and partnerships. The leadership team, including experienced professionals like Chief Technical Officer Ann L. Lee, is dedicated to enhancing the company's technological capabilities and expanding operations.

Company Stage

N/A

Total Funding

$596M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

1%

1 year growth

6%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $161 million PIPE offering and previous substantial funding rounds indicate strong investor confidence and financial stability.
  • Partnerships with organizations like the Cystic Fibrosis Foundation provide both financial support and validation of Prime Medicine's technology.
  • Successful preclinical data in non-human primates demonstrate the potential efficacy and safety of Prime Editing, bolstering the company's scientific credibility.

What critics are saying

  • The highly competitive biotech landscape requires continuous innovation to maintain a leading position.
  • Regulatory hurdles and the complexity of clinical trials could delay the commercialization of Prime Editing therapies.

What makes Prime Medicine unique

  • Prime Medicine's Prime Editing technology offers unparalleled precision in DNA modification, setting it apart from other gene-editing techniques like CRISPR.
  • The company's focus on developing one-time curative therapies for genetic diseases provides a unique value proposition in the biotech sector.
  • Strategic collaborations with research institutions and pharmaceutical companies enhance Prime Medicine's ability to innovate and bring its technology to market.